Drug Profile
Research programme: glutamate modulators - Biohaven Pharmaceuticals
Alternative Names: Glutamatergic agents - Biohaven; Neuropsychiatric disorder therapeutics - Biohaven; Riluzole - BiohavenLatest Information Update: 13 Oct 2022
Price :
$50
*
At a glance
- Originator Fox Chase Chemical Diversity Center; Yale University
- Class Benzothiazoles; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Glutamate receptor antagonists; Glutamate release inhibitors; Voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mental disorders